Following a re-evaluation, the EMA has recommended Eisai and Biogen’s Alzheimer’s therapy Leqembi for a subgroup of patients.

Discover the top sales and marketing intelligence solutions tailored for the pharmaceutical industry. Download our guide to predictive analytics and data-driven insights.

The company has discontinued the Phase I/II trial of its only clinical candidate due to a potential “unfavourable ...

Adaptimmune’s Phase II IGNYTE-ESO trial investigating experimental T cell therapy lete-cel has achieved its primary endpoint.

Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.

The US Food and Drug Administration (FDA) has granted accelerated approval for PTC Therapeutics’ KEBILIDI, the first gene ...

In Shanghai, more than 300 industry leaders, experts, and partners met to discuss the latest trends in the data centre ...

Flagship Pioneering -founded Valo Health has announced the appointment of Dr Brian Alexander as its new CEO. Additionally, ...

Developed in partnership with CRScube, a renowned South Korean clinical research technology provider, the purpose-built new ...

BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

Syros noted that SELCT-MDS-1 Phase III trial’s failure to meet its endpoint constituted a default event under its secured ...

Lyophilization plays a crucial role in successful biologic molecule development, but what is lyophilization – and how can it ...